For TFRC, its IHC results are similar to its MS in the tumour, indicating that as a tumour biomarker, its abundance sensitively responds to CP treatment, while the changes of IHC and MS signals, in stroma, are not at the same pace, wherein no alteration in IHC and a slight increase in MS were detected. The gene discussed is TFRC; the disease is neoplasm.